[1] Chan HL,SungJJ.Hepatocellular carcinoma and hepatitis B virus.Semin Liver Dis,2006,26:153-161.
[2] Wong VW,Chan SL,Mo F,et al.Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers.J Clin oncol,2010,28:1660-1665.
[3] 黄正京,周脉耕,王黎君.中国肝癌死亡率和乙肝病毒表面抗原携带率的地理分布研究.疾病监测,2007,22:242-245.
[4] Galbraith RM,Eddleston AL,Williams R,et al.Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy.Lancet 1975,2:528-530.
[5] Nagington J.Reactivation of hepatitis B after transplantation operations.Lancet,1977,1:558-560.
[6] Hoofnagle JH.Reactivation of hepatitis B.Hepatology,2009,49:S156-S165.
[7] American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.Gastroenterology,2015,148:221-244.
[8] Shouval D,Shibolet O.Immunosuppression and HBV reactivation.Semin Liver Dis,2013,33:167-177.
[9] Yeo W,Zee B,Zhong S,et al.Comprehensive analysis of risk factors associating with Hepatitis B virus(HBV)reactivation in cancer patients undergoing cytotoxic chemotherapy.Br J Cancer,2004,90:1306-1311.
[10] Hui CK,Bowden S,Jackson K,et al.Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy.Blood,2005,105:2616-2617.
[11] Wang DK,Tanaka Y,Lai CL,et al.Hepatitis B virus corerelated antigens as markers for monitoring chronic hepatitis B infection.J Clin Microbiol,2007,45:3942-3947.
[12] Hoofnagle JH.Reactivation of hepatitis B.Hepatology 2009,49:S156-S165.
[13] Artz AS,Somerfield MR,Feld JJ,et al.American society of clinical oncology provisional clinical opinion:chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.J Clin Oncol,2010,28:3199-3202.
[14] Nayernama A,Waldron P,Rand M,et al.Hepatitis B virus reactivation in CD20 antibody-treated patients:evaluation of post market data from the FDA adverse event reporting system.Presemted at: Proceedings from AASLD/NIH Emerging Trends Conference on HBV Reactivation:March 21,2013 Crystal City,VA,21:105-106.
[15] Yeo W,Chan TC,Leung NW,et al.Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.J Clin Oncol,2009,27:605-611.
[16] Pei SN,Chen CH,Lee CM,et al.Reactivation of hepatitis B virus following rituximab-based regimens:a serious complication in both HBsAg-positive and HBsAg negative patients.Ann Hematol,2010,89:255-262.
[17] Mitka M.FDA:Increased HBV reactivation risk with ofatumumab or rituximab.JAMA,2013,310:1664.
[18] Perez-Alvarez R,Diaz-Lagares C,García-Hernández F,et al.Hepatitis B virus (HBV)reactivation in patients receiving tumor necrosis factor(TNF)-targeted therapy:analysis of 257 cases.Medicine(Baltimore),2011,90:359-371.
[19] Schalm SW,Summerskill WH,Gitnick GL,et al.Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis B S antigen.Gut,1976,17:781-786.
[20] Scullard GH,Smith CI.Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B.Gastroenterology,1981,81:987-991.
[21] Kim TW.Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated withcorticosteroids.Respirology,2010,15:1092-1097.
[22] Flowers MA,Heathcote J,Wanless IR,et al.Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy.Ann Intern Med,1990,112:381-382.
[23] Loomba R,Rowley A,Wesley R,et al.Systematic review:the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.Ann Intern Med,2008,148:519-528.
[24] Huang H,Li XY,Li HR,et al.Preventing hepatitis B reactivation in HBs Ag-positive patients with untreated diffuse large B-cell lymphoma with R-CHOP chemotherapy:a prospective study to compare entecavir and lamivudine.J Clin Oncol,2013,31(suppl):A8503.
[25] Hepatology Division,Baylor University Medical Center.American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.Gastroenterology,2015,148:221-244. |
